NEW YORK (GenomeWeb News) – German biopharmaceutical firm Probiodrug and the VU University Medical Center Alzheimer Center in The Netherlands today announced a collaboration to evaluate molecular biomarker assays for Alzheimer's disease.

The assays will be assessed for their diagnostic, pharmacodynamic, and therapeutic use. Cerebrospinal fluid samples from well-characterized Alzheimer's disease patients at different stages of the illness will be analyzed and compared with CSF from age-matched control samples as part of the collaboration.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.